Gero develops an AI-driven drug discovery platform that applies physics-based modelling and generative AI to identify mechanisms and targets underlying ageing and multiple chronic conditions. The platform leverages longitudinal data from approximately 10 million medical records to inform target discovery. Gero is advancing programs aimed at slowing ageing and is supporting those programs through preclinical development. The company has pharmaceutical partnerships including a collaboration with Roche’s Chugai that featured an upfront payment and up to $250 million in milestones, and an alliance with Pfizer. Financially, Gero has now raised $17 million in its most recent round, bringing total equity funding to $34 million. The company is based in Singapore.

Total raised

$30M

Funding rounds

4

Latest round

Series B

Latest activity

Jun 2026